Use of pimobendan for the reduction of heart size in mammals suffering from heart failure

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9889148
SERIAL NO

14175175

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BOEHRINGER INGELHEIM VETMEDICA GMBHGERMAN INGELHEIM INGELHEIM RHINELAND-PALATINATE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Daemmgen, Juergen Ochsenhausen, DE 21 181
Joens, Olaf Ober-Hilbersheim, DE 9 123
Kleemann, Rainer Ingelheim am Rhein, DE 7 76

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 13, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 13, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00